NO20053548L - Pulvermedikament for inhalering inneholdende et tiotropiumsalt og salmeterolxinafoat. - Google Patents

Pulvermedikament for inhalering inneholdende et tiotropiumsalt og salmeterolxinafoat.

Info

Publication number
NO20053548L
NO20053548L NO20053548A NO20053548A NO20053548L NO 20053548 L NO20053548 L NO 20053548L NO 20053548 A NO20053548 A NO 20053548A NO 20053548 A NO20053548 A NO 20053548A NO 20053548 L NO20053548 L NO 20053548L
Authority
NO
Norway
Prior art keywords
powder
salmeterol xinafoate
tiotropium salt
inhalation containing
inhalation
Prior art date
Application number
NO20053548A
Other languages
English (en)
Inventor
Rainer Soyka
Peter Sieger
Michael Walz
Michael Trunk
Hagen Grabner
Mareke Hartig-Heimel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32404034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053548(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20053548L publication Critical patent/NO20053548L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives pulverformede tilberedninger for inhalasjon, inneholdende et tiotropiumsalt og salmeterolxinafoat, fremgangsmåter for fremstilling av disse, samt deres anvendelse til fremstilling av et legemiddel til behandling av luftveissykdommer, særlig til behandling av COPD (chronic obstructive pulmonary disease) og astma.
NO20053548A 2002-12-20 2005-07-19 Pulvermedikament for inhalering inneholdende et tiotropiumsalt og salmeterolxinafoat. NO20053548L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10259912 2002-12-20
PCT/EP2003/013691 WO2004058233A1 (de) 2002-12-20 2003-12-04 Pulverförmige arzneimittel zur inhalation enthaltend ein tiotropiumsalz und salmeterolxinafoat

Publications (1)

Publication Number Publication Date
NO20053548L true NO20053548L (no) 2005-09-02

Family

ID=32404034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053548A NO20053548L (no) 2002-12-20 2005-07-19 Pulvermedikament for inhalering inneholdende et tiotropiumsalt og salmeterolxinafoat.

Country Status (21)

Country Link
EP (1) EP1581198A1 (no)
JP (1) JP2006516135A (no)
KR (1) KR20050086930A (no)
CN (1) CN1728988B (no)
AU (1) AU2003288226B2 (no)
BR (1) BR0317443A (no)
CA (1) CA2510779A1 (no)
DE (1) DE10351663A1 (no)
EA (1) EA010588B1 (no)
EC (1) ECSP055855A (no)
FR (1) FR2848849B1 (no)
HR (1) HRP20050570A2 (no)
IT (1) ITMI20032473A1 (no)
MX (1) MXPA05006519A (no)
NO (1) NO20053548L (no)
NZ (1) NZ541303A (no)
PL (1) PL376231A1 (no)
RS (1) RS20050484A (no)
UA (1) UA83813C2 (no)
WO (1) WO2004058233A1 (no)
ZA (1) ZA200503692B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4342426B2 (ja) * 2004-11-24 2009-10-14 科研製薬株式会社 イトラコナゾール経口投与用製剤
JP2009504603A (ja) * 2005-08-06 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チオトロピウム塩とサルメテロールの塩とを組合せて投与する呼吸困難の治療方法
RS52663B2 (sr) * 2005-12-19 2018-05-31 Sicor Inc Nova kristalna forma tiotropijum bromida i proces njene pripreme
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
DE102007036411A1 (de) * 2007-07-20 2009-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
EP3880251B1 (en) * 2018-11-13 2025-04-09 Cocrystal Pharma, Inc. Formulations of influenza therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1229892A (en) * 1992-02-11 1993-09-03 Glaxo Group Limited Benzenedimethanol derivative suitable for micronisation
CN1056974C (zh) * 1992-02-11 2000-10-04 格拉克索公司 适宜于微粒化的药物材料的制备方法
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10056104A1 (de) * 2000-11-13 2002-05-23 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols
DE10104367A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
WO2003013633A1 (en) * 2001-08-09 2003-02-20 Glaxo Group Limited Inhalation device with a pharmaceutical composition
MXPA04002401A (es) * 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Nuevos medicamentos para inhalacion.

Also Published As

Publication number Publication date
ITMI20032473A1 (it) 2004-06-21
BR0317443A (pt) 2005-11-16
JP2006516135A (ja) 2006-06-22
WO2004058233A1 (de) 2004-07-15
UA83813C2 (ru) 2008-08-26
CA2510779A1 (en) 2004-07-15
ECSP055855A (es) 2005-11-22
MXPA05006519A (es) 2005-08-26
FR2848849B1 (fr) 2007-01-05
RS20050484A (sr) 2007-11-15
DE10351663A1 (de) 2004-07-01
HRP20050570A2 (en) 2006-07-31
AU2003288226B2 (en) 2010-01-07
FR2848849A1 (fr) 2004-06-25
EP1581198A1 (de) 2005-10-05
EA010588B1 (ru) 2008-10-30
EA200500902A1 (ru) 2006-02-24
NZ541303A (en) 2008-11-28
PL376231A1 (en) 2005-12-27
CN1728988A (zh) 2006-02-01
ZA200503692B (en) 2006-10-25
KR20050086930A (ko) 2005-08-30
CN1728988B (zh) 2010-04-28
AU2003288226A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
NO20053548L (no) Pulvermedikament for inhalering inneholdende et tiotropiumsalt og salmeterolxinafoat.
MY123544A (en) New inhalable powder containing tiotropium
MY155912A (en) New inhalable powder containing tiotropium
MY143517A (en) Formoterol superfine formulation
CY1114157T1 (el) Αλατα του τιοτροπιου, μεθοδος για την παραγωγη τους και φαρμακευτικα σκευασματα που τα περιεχουν
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
NO20061441L (no) Nye tiotropiumsalter, metoder for deres fremstilling, og farmasoytiske formuleringer inneholdende disse
NO20051956L (no) Salmeterol superfin formulering
NO20073909L (no) Forstover-formulering
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
DE60308497D1 (de) Pulverzubereitungen zur inhalation
WO2005007134A8 (de) Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum
TH73286A (th) เกลือไทโอโทรเปียมใหม่ กรรมวิธีเพื่อการเตรียม และสารผสมยาของสารนั้น

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application